Margriet Bogerd

Margriet Bogerd

Auto-generated profile, based on publicly available information

Margriet Bogerd

Amsterdam UMC

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 March 2025 in European Heart Journal: Acute Cardiovascular Care
Verified
Journal Article
Open access
EPElma J Peters
Elma J Peters
JKJoakim B Kunkel
Joakim B Kunkel
MBMargriet Bogerd
Margriet Bogerd
SBSanne Ten Berg
Sanne Ten Berg
MTMarijke J C Timmermans
Marijke J C Timmermans
Jose HenriquesJose Henriques
Jose Henriques
Aims: Mortality in patients with acute myocardial infarction-related cardiogenic shock (AMICS) is high, but a widely accepted tool for individual risk assessment is lacking. A reliable prediction model could assist in clinical decision-making, patient selection for clinical trials, and comparison of AMICS populations. Therefore, the aim of this study was to develop and externally validate a prediction model for 30-day mortality in AMICS patients. Methods and results: This retrospective cohort study included patients from 2017 to 2021 (development cohort) and 2010–2017 (validation cohort). Patients with AMICS undergoing percutaneous coronary intervention in The Netherlands were identified using the Netherlands Heart Registration. International validation was performed in the Danish Retroshock registry. The main outcome was 30-day mortality. Among 2261 patients, the median age was 67 years [interquartile range (IQR) 58–75], and 1649 (73%) were male. The mortality rate at 30 days was 39% (n = 886). Significant predictors for mortality were: initial lactate, glucose, renal function, haemoglobin, age, blood pressure, heart rate, intubation prior to PCI, intervention in the left main coronary artery, and successful revascularization. The AUC of the initial model was 0.81 (0.79–0.83). The external validation cohort included 1393 patients with 1050 (75%) male and a median age of 67 years (IQR 59–75). The 30-day mortality rate was 49% (n = 680). The model showed good performance on the external validation with an AUC of 0.73 (0.70–0.76). Conclusion: A prediction model was developed and externally validated using data from two large national registries. The model demonstrated good performance and is suitable for clinical decision-making and quality purposes in AMICS.

17 February 2025 in Open Heart
Verified
Journal Article
Open access
PDF file
MBMargriet Bogerd
Margriet Bogerd
AGAlexander M Griffioen
Alexander M Griffioen
JBJeroen J H Bunge
Jeroen J H Bunge
EPElma J Peters
Elma J Peters
SBSanne Ten Berg
Sanne Ten Berg
OROn behalf of the PCI Registration Committee of the Netherlands Heart Registration
On behalf of the PCI Registration Committee of the Netherlands Heart Registration
Background: Despite limited beneficial evidence, mechanical circulatory support (MCS) is commonly used in patients with acute myocardial infarction-related cardiogenic shock (AMI-CS). In this Dutch registry, we investigated MCS usage, associated patient characteristics and clinical outcomes. Methods: This real-world, multicentre registry included CS patients undergoing percutaneous coronary intervention between 2017 and 2021 in 14 Dutch hospitals. The impact on clinical outcomes was analysed after 1:1 average propensity-score (aPS) matching. Results: This AMI-CS registry included 2217 patients with a mean age of 66.4 (±12.3) years and predominantly male (72.8%, n=1613). MCS was deployed in 516 patients (23.3%), of which the intra-aortic balloon pump was used most frequently (n=253, 49.0%). Impella was used in 94 patients (18.2%), extracorporeal membrane oxygenation in 68 patients (13.2%) and 95 patients (18.4%) received multiple devices. Patients receiving MCS were younger (64.2 vs 67.0, p<0.01), presented with lower mean arterial pressures (74.7 vs 78.4 mm Hg, p<0.01), higher heart rates (88.3 vs 81.7 beats per minute, p<0.01) and higher initial lactate levels (6.4 vs 5.4 mmol/L, p<0.01). The percentage of resuscitated patients was comparable among MCS and non-MCS patients (38.6% vs 42.2%, p=0.17). The 30-day mortality rate was higher in MCS patients (55.0% vs 34.7%, p<0.01). After aPS-matching (n=970), 30-day mortality remained higher for MCS patients (53.8% vs 44.7%, p<0.01), with an associated OR of 1.44 (95% CI 1.12 to 1.85, p<0.01). Conclusions: Despite limited evidence, MCS was used in a fourth of all AMI-CS patients. MCS usage was associated with an increased 30-day mortality in this real-world setting, even after propensity-matching.

12 February 2025 in European Heart Journal: Acute Cardiovascular Care
Verified
Journal Article
Open access
MBMargriet Bogerd
Margriet Bogerd
LHLuc Ten Hoorn
Luc Ten Hoorn
SBSanne Ten Berg
Sanne Ten Berg
EPElma J Peters
Elma J Peters
AEAnnemarie E Engström
Annemarie E Engström
Jose HenriquesJose Henriques
Jose Henriques
Aims: Microaxial flow pump and venoarterial extracorporeal membrane oxygenation (VA-ECMO) are increasingly used in infarct-related cardiogenic shock. This study provides a comparative overview of real-world resource utilization associated with these devices (PROSPERO: CRD42024505174). Methods and results: EMBASE, MEDLINE, and Cochrane Library were sought from inception to 13 November 2024 for studies reporting at least one primary outcome, including intensive care unit (ICU) length of stay (LOS), hospital LOS, in-hospital costs, and discharge destination. In-hospital mortality was included as secondary outcome. This study was guided by the PRISMA-2020 guideline. Study selection and data extraction were independently performed by two researchers. Risk-of-bias assessments were done using the Newcastle-Ottawa-Scale. Data were pooled using random-effect models. In total, 12 retrospective cohorts were identified encompassing 92 262 microaxial flow pump- and 16 474 VA-ECMO patients data. The meta-analysis of hospital LOS and in-hospital costs revealed favourable results for the microaxial flow pump, with mean differences (MD) of −5.3 days (95% CI: −6.6, −4.1) and −$113 983 (95% CI: −$143 153, −$84 812), respectively. Microaxial flow pump survivors were also 45% more likely to be discharged home (95% CI: 1.28–1.64). Intensive care unit-length of stay was reported by one study, reporting a 10 days MD in favour of the microaxial flow pump. The averaged in-hospital mortality rates were 44% and 57% for the microaxial flow pump and VA-ECMO, respectively. An inherent limitation of observational studies is confounding by indication. Conclusion: Microaxial flow pump was associated with lower resource utilization compared with VA-ECMO. Resource utilization should be incorporated in prospective RCTs and taken into account when considering these devices.

6 May 2025 in Journal of the American Heart Association
Verified
Journal Article
Open access
MBMargriet Bogerd
Margriet Bogerd
Jose HenriquesJose Henriques
Jose Henriques

6 October 2026 in Journal of the American Heart Association
Verified
Journal Article
Open access
MBMargriet Bogerd
Margriet Bogerd
SBSanne Ten Berg
Sanne Ten Berg
EPElma J. Peters
Elma J. Peters
MTMarijke J. C. Timmermans
Marijke J. C. Timmermans
RDRonak Delewi
Ronak Delewi
LRLex Ruiters
Lex Ruiters